Program
elifibranor
Also written as “Elafibranor”, “GFT505 80mg” and “elafibranor”.
Its studies are mostly in Liver Cirrhosis, Biliary · Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Diabetes Mellitus, Type 2 · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfit | 160 open or running | phase 3since Feb 16, 2016 | Dec 13, 2010 | none ahead |
| Ipsen | 85 open or running | phase 3since Aug 21, 2020 | Aug 21, 2020 | Dec 17, 2026phase 3 · NCT06730061 |
Also a collaborator on its studies: naturalpha, premier-research-group-plc, eurofins-optimed and phinc-development.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Dec 13, 2010.
- Mar 28, 2017Phase 2 study in Liver Cirrhosis, BiliaryGenfit · NCT03124108 · 45 enrolled · United States, France, Germany and more
- Nov 30, 2018Phase 1 study in Liver DiseasesGenfit · NCT03765671 · 30 enrolled · United States
- Feb 15, 2019Phase 1 study in Renal InsufficiencyGenfit · NCT03844555 · 23 enrolled · France, Romania
- Mar 13, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGenfit · NCT03883607 · 10 enrolled · United States
- May 15, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGenfit · NCT03953456 · 17 enrolled · Netherlands
- Jun 11, 2019Phase 1 study in Drug-drug InteractionGenfit · NCT03985969 · 26 enrolled · France
- Nov 19, 2019Phase 1 study in GeriatricsGenfit · NCT04171752 · 21 enrolled · France
- Aug 21, 2020Ipsen's first study: phase 3 study in Liver Cirrhosis, BiliaryNew to IpsenIpsen · NCT04526665 · 161 enrolled · United States, Argentina, Belgium and more
- Sep 14, 20222 phase 1 studiesIpsen · NCT05543369, NCT05564208
- Nov 22, 2022Phase 2 study in Cholangitis, SclerosingIpsen · NCT05627362 · 68 enrolled · United States, Canada, Germany and more
- Aug 22, 2023Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06016842 · 276 planned · United States, Argentina, Australia and more
- Apr 22, 2024Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06383403 · 92 enrolled · United States, Czechia, France and more
- Dec 3, 2024Phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06730061 · 18 enrolled · Japan
- Jan 28, 2026Phase 3 study in Cholangitis, SclerosingIpsen · NCT07387549 · 350 planned · United States, Argentina, Australia and more
Ahead
- Dec 17, 2026Primary completion: phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06730061
- May 31, 2029Primary completion: phase 3 study in Liver Cirrhosis, BiliaryIpsen · NCT06016842
- Apr 30, 2031Primary completion: phase 3 study in Cholangitis, SclerosingIpsen · NCT07387549
- Sep 23, 2031Primary completion: phase 2 study in Cholangitis, SclerosingIpsen · NCT05627362
TargetBeta
“An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity”NCIt, by rule
“Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| seladelparrule | Gilead Sciences | phase 3 | 14 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07387549Cholangitis, Sclerosing · United States, Argentina, Australia and more | 3 | Recruiting | Ipsen | Apr 30, 2031 | 350 |
| NCT06730061Liver Cirrhosis, Biliary · Japan | 3 | Active, not recruiting | Ipsen | Dec 17, 2026 | 18 |
| NCT06383403Liver Cirrhosis, Biliary · United States, Czechia, France and more | 3 | Completed | Ipsen | Jun 16, 2026 | 92 |
| NCT06016842Liver Cirrhosis, Biliary · United States, Argentina, Australia and more | 3 | Recruiting | Ipsen | May 31, 2029 | 276 |
| NCT05627362Cholangitis, Sclerosing · United States, Canada, Germany and more | 2 | Active, not recruiting | Ipsen | Sep 23, 2031 | 68 |
| NCT05564208Healthy Participants · France | 1 | Completed | Ipsen | Dec 30, 2022 | 34 |
| NCT05543369Healthy Volunteers · United States | 1 | Completed | Ipsen | Mar 10, 2023 | 48 |
| NCT04526665Liver Cirrhosis, Biliary · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Ipsen | Jun 1, 2023 | 161 |
| NCT04171752Geriatrics · France | 1 | Completed | Genfit | Mar 22, 2020 | 21 |
| NCT03985969Drug-drug Interaction · France | 1 | Completed | Genfit | Mar 15, 2020 | 26 |
| NCT03953456Non-alcoholic Fatty Liver Disease · Netherlands | 2 | Terminated | Genfit | Mar 11, 2020 | 17 |
| NCT03883607Non-alcoholic Fatty Liver Disease · United States | 2 | Terminated | Genfit | Jun 16, 2020 | 10 |
| NCT03844555Renal Insufficiency · France, Romania | 1 | Completed | Genfit | Mar 15, 2020 | 23 |
| NCT03765671Liver Diseases · United States | 1 | Completed | Genfit | Jun 7, 2019 | 30 |
| NCT03124108Liver Cirrhosis, Biliary · United States, France, Germany and more | 2 | Completed | Genfit | Oct 31, 2018 | 45 |
| NCT02704403Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Terminated | Genfit | Oct 28, 2020 | 2,157 |
| NCT02142127Healthy · Belgium | 1 | Completed | Genfit | Jun 2014 | 6 |
| NCT02091310Healthy Volunteers · France | 1 | Completed | Genfit | Dec 2014 | 200 |
| NCT01694849Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Genfit | Feb 2015 | 275 |
| NCT01474161Diabetes Mellitus, Type 2 · France | 1 | Completed | Genfit | Nov 2012 | 96 |
| NCT01275469Glucose Intolerance · France | 2 | Completed | Genfit | Dec 2009 | 47 |
| NCT01271751Obesity, Abdominal · France, Romania, Tunisia | 2 | Completed | Genfit | Sep 2009 | 96 |
| NCT01271777Insulin Resistance · France | 2 | Completed | Genfit | Nov 2011 | 22 |
| NCT01261494Diabetes Mellitus, Type 2 · Bosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of and more | 2 | Completed | Genfit | Jun 2011 | 97 |
How it is read
Names in the registry
- “Elafibranor”, 8 entries
- “GFT505 80mg”, 5 entries
- “elafibranor”, 4 entries
- “Elafibranor 80mg”, 2 entries
- “Elafibranor 80 mg”, 2 entries
Conditions, from the studies’ own filings
- Liver Cirrhosis, Biliary, 5 studies
- Non-alcoholic Fatty Liver Disease, 4 studies
- Cholangitis, Sclerosing, 2 studies
- Diabetes Mellitus, Type 2, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.